Duyuru • Aug 05
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural And Cognitive Deficits In A Mouse Model Of Fragile X Marvel Biosciences Corp. and its wholly owned subsidiary Marvel Biotechnology Inc. announced positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation. By demonstrating statistically significant improvements in both behavioural and cognitive function in a Fragile X mouse model, including durable carry-over effects after treatment ceased, MB-204 has now generated compelling efficacy data across three independent preclinical models of autism spectrum disorder (ASD), including Rett syndrome (Mecp2), the Oprm1 model of ASD, and now Fragile X syndrome (Fmr1). Collectively, these results further strengthen the scientific foundation supporting MB-204's advancement toward clinical trials while expanding its potential commercial opportunity across multiple orphan neurological indications with significant unmet medical need. The study was conducted through the FRAXA Drug Validation Initiative (FRAXA-DVI), an independent program that evaluates promising therapeutic candidates for Fragile X syndrome. The study evaluated MB-204, Marvel’s lead compound, in low- and high-dose treatment groups administered orally once daily in FMR1 knockout (KO) mice. FMR1 mice were treated for approximately two weeks and subjected to a standard battery of model-specific behavioural and cognitive tests, then retested two weeks after treatment ceased to study the carry-over effect of the drug. Overall, MB-204 restored every behavioural and cognitive endpoint studied in Fragile X mice toward wild-type (normal) levels, including improvements in novel object recognition (cognition), open-field test (locomotor activity), self-grooming (stereotypy), nesting (hippocampal dependent activity of daily living), hyphoneophagia (anxiety). Key highlights included: After Two Weeks On Treatment: MB-204 produced clear dose-dependent behavioural effects in the Fmr1 knockout mouse on every endpoint, with the high-dose group showing the strongest and most consistent efficacy. Animals receiving the high-dose treatment generated response patterns statistically consistent with wildtype-like performance (WT) in open-field test activity, self-grooming, nesting and hyponeophagia. This latest preclinical success in Fragile X syndrome marks the third autism-related model in which MB-204 has demonstrated the ability to restore behavioural and cognitive function toward normal levels, providing further validation of the drug's mechanism of action and strengthening the Company’s core investment thesis. Combined with previously reported positive results in the Rett syndrome (Mecp2) and Oprm1 ASD models, these findings continue to build a compelling preclinical package supporting the advancement of MB-204 toward clinical trials. The Company has also completed preclinical evaluation of MB-204 in a Shank3 model of Phelan-McDermitt syndrome and is awaiting final statistical analysis of the results. Marvel expects to report those results in a future announcement. Duyuru • Jul 17
Marvel Biosciences Corp. announced that it expects to receive CAD 3 million in funding Marvel Biosciences Corp. has announced non-brokered private placement to issue 20,000,000 at the price of CAD 0.15 for the gross proceeds of CAD 3,000,000 on July 16, 2026. Each warrant entitles the holder thereof to acquire one additional common share and one common share purchase warrant at an exercise price of CAD 0.20 per warrant on the sixty first day after the closing date of the offering for a period of 1 year from the date of issuance. The offering is subject to regulatory approvals, including approval from the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The Units offered under the Listed Issuer Financing Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws. Shareholders or investors who may wish to participate in the Offering and who seek further details about the Offering should contact the Company’s Chief Executive Officer, J. Roderick Matheson, at 403 770 2469. In connection with the Offering, the Corporation will pay a finder’s fees equal to up to 7% of the gross proceeds raised from those investors introduced by the finder to the Offering, payable in cash, and finder’s warrants in an amount equal to 7% of the aggregate number of Units in relation to subscribers introduced by any particular finder, with each Finder’s Warrant being exercisable to acquire one Common Share at a price of CAD 0.20 per share commencing on the sixty first (61st) day after the Closing Date for a period of one year from the Closing Date provided that if, at any time after the date that is sixty-one days following the Closing Date. The closing of the Offering may occur in one or more tranches, the first of which is expected to close on or about August 14, 2026. Closing of the Offering is subject to receipt of all regulatory approvals, including approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. Duyuru • Jun 10
Marvel Biosciences Corp. Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for Mb-204 Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026. The patent is expected to be granted shortly after August 28, 2026. The Australian notice of allowance further strengthens Marvel's global composition-of-matter patent portfolio for MB-204, reinforcing the Company's intellectual property position as it advances into Phase I clinical development following positive preclinical efficacy and toxicology results. Such includes recent preclinical studies in Rett syndrome models that demonstrated that MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints and produced sustained therapeutic benefits that persisted after treatment cessation, suggesting the potential for disease-modifying effects. Broadening patent protection across key pharmaceutical markets enhances the asset's commercial value by extending market exclusivity, reducing competitive risk, and increasing its attractiveness for potential licensing, partnering, and strategic investment opportunities. Marvel Biosciences Corp. has also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of its patent estate. MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline which is used for the treatment of Parkinson’s Disease. MB-204 has demonstrated superior pharmacokinetics and completed pre-clinical toxicology testing and has shown excellent pre-clinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around 1 in 36 children at age 8 have been diagnosed with autism spectrum disorder which underscores the urgency for new agents. The patent advancement follows a series of significant achievements in 2026, including the granting of U.S. and Japanese composition-of-matter patents for MB-204, the selection of Novotech as the Company's contract research organization for its planned Phase I clinical trial, the securing of non-dilutive funding support from Alberta Innovates, strategic investment participation from 5 Horizons Ventures, and the development of novel pediatric-friendly liquid formulations that may further expand the Company's intellectual property estate. Collectively, these achievements continue to validate Marvel's scientific platform, strengthen its credibility within the biotechnology sector, and support the Company's transition from a pre-clinical organization to a clinical-stage drug development company. Duyuru • Apr 18
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding On April 17, 2026, Marvel Biosciences Corp closed the transaction. Duyuru • Apr 17
Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental Disorders Marvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points. Duyuru • Dec 08
Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026 Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026. 
